Zoetis (ZTS) is back in focus after Q2 2026 earnings topped EPS expectations, even as sales stayed broadly unchanged and management cut full year guidance while appointing veteran executive Jay Saccaro as CFO and COO.

At a share price of US$72.66, Zoetis is trading well below where it started the year, with the share price down 42.3% year to date and the 1 year total shareholder return down 49.7%. This points to weaker momentum even after recent interest around the earnings miss on sales, lowered 2026 guidance and the appointment of Jay Saccaro as CFO and COO.

If you are reassessing Zoetis after this reset, it can help to widen the lens and compare it with other healthcare companies using AI, including those in animal health, by reviewing the 43 healthcare AI stocks

The reset in Zoetis, with a sharp share price fall and lower 2026 guidance, leaves a very different entry point than a year ago. Is it more sensible to commit capital now, or to wait for an even cheaper price before acting?

Most Popular Narrative: 21.8% Undervalued

According to one widely followed Zoetis narrative, a fair value of $92.92 sits well above the last close at $72.66, which puts a spotlight on how that gap is being justified.

On one hand it’s not a business that’s going to grow much; on the other hand, it’s also not likely to collapse catastrophically. Double-edged sword. The company cites generics as a potential risk in its financial statements. I’m not sure how much of this could be attributable to the 11% YoY decline in Pet segment revenues, but this is just something to watch out for if you’re interested in investing in the business.

The fair value hinges on steady but modest growth, resilient margins and a specific view on how earnings quality supports that profit profile. Curious which revenue mix and profitability assumptions sit underneath that $92.92 figure, and how they square with a business that is described as slow growing yet durable.

Result: Fair Value of $92.92 (UNDERVALUED)

However, Zoetis still faces pressure from generic competition, and any further weakness in US Companion Animal revenues could quickly challenge that 21.8% undervaluation thesis.

Next Steps

Given the mix of caution and optimism around Zoetis in this article, it may be helpful to review the information and form your own view. To see both sides of the story in one place, review the 4 key rewards and 1 important warning sign

Looking for more investment ideas beyond Zoetis?

If Zoetis has you rethinking your portfolio, now is a good moment to broaden your watchlist and line up other potential opportunities before the next move.

• Spot potential bargains early by scanning companies that look mispriced on quality and valuation using the 52 high quality undervalued stocks
• Strengthen your downside protection by focusing on businesses with robust finances through the solid balance sheet and fundamentals stocks screener (48 results)
• Hunt for future standouts by checking the screener containing 21 high quality undiscovered gems before other investors catch on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.